Other Restructuring

Ref: NEPHROPLUS/SE/85 September 18, 2026 To To BSE Limited Na(cid:415)onal Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Lis(cid:415)ng Centre Through: NEAPS Subject: Disclosure under Regula(cid:415)on 30 of the SEBI (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015 - Ra(cid:415)onalisa(cid:415)on and Consolida(cid:415)on of the Company’s Step-down Subsidiaries in the Philippines Dear Sir/Madam, Pursuant to Regula(cid:415)on 30 read with Para A of Part A of Schedule III of the SEBI (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015 (“SEBI Lis(cid:415)ng Regula(cid:415)ons”), we hereby inform that the Board of Directors of Nephrocare Health Services Limited (“Company”), at its mee(cid:415)ng held today, i.e., Friday, September 18, 2026, has approved the proposed ra(cid:415)onalisa(cid:415)on and consolida(cid:415)on of the Company’s step-down subsidiaries in the Philippines, subject to compliance with applicable laws and receipt of such statutory, regulatory, corporate and other approvals as may be required. The proposed ra(cid:415)onalisa(cid:415)on and consolida(cid:415)on is intended to simplify the exis(cid:415)ng structure of the Group's Philippine opera(cid:415)ons, thereby improving opera(cid:415)onal, administra(cid:415)ve and cost efficiencies and strengthening management and governance oversight. This simplified structure will, in turn, be more scalable and be(cid:425)er aligned with the Company's interna(cid:415)onal growth strategy. The details as required under Regula(cid:415)on 30 of the SEBI Lis(cid:415)ng Regula(cid:415)ons read with the applicable SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFDPOD2/ I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure A. The Company shall make further disclosures/updates in rela(cid:415)on to the proposed ra(cid:415)onalisa(cid:415)on and consolida(cid:415)on, as may be required under the SEBI Lis(cid:415)ng Regula(cid:415)ons. The mee(cid:415)ng of Board of Directors commenced at 03:20 p.m. IST and concluded at about 03:45 p.m. IST. The above informa(cid:415)on is also being made available on the website of the Company at www.nephroplus.com. Kindly take the above informa(cid:415)on on record. Yours faithfully, For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 ANNEXURE A Details pursuant to Regula(cid:415)on 30 read with Para A of Part A of Schedule III of the SEBI Lis(cid:415)ng Regula(cid:415)ons S. Par(cid:415)culars Details 1. Details and reasons for Nephrocare Health Care Services Philippines, Inc. restructuring (“Nephrocare PH”), a step-down subsidiary of the Company held through Nephrocare Health Services Interna(cid:415)onal Pte. Ltd., Singapore, operates the Group’s business in the Philippines through mul(cid:415)ple wholly-owned subsidiaries. As part of the Group’s ongoing efforts to simplify its corporate structure and enhance opera(cid:415)onal efficiency, the Group proposes to ra(cid:415)onalise and consolidate its exis(cid:415)ng Philippine subsidiary structure into a smaller number of opera(cid:415)ng en(cid:415)(cid:415)es. The proposed consolida(cid:415)on is expected to streamline administra(cid:415)ve and compliance processes, op(cid:415)mise costs and strengthen management and governance oversight. The consolida(cid:415)on will be implemented in a phased manner, subject to applicable laws and receipt of requisite approvals in India and the Philippines. 2. Quan(cid:415)ta(cid:415)ve and/or qualita(cid:415)ve The proposed ra(cid:415)onalisa(cid:415)on and consolida(cid:415)on is an effect of restructuring internal reorganisa(cid:415)on of the Group’s Philippine opera(cid:415)ons, aimed at simplifying the exis(cid:415)ng en(cid:415)ty structure and enhancing opera(cid:415)onal, administra(cid:415)ve and compliance efficiencies. The transac(cid:415)on will not involve any third-party investor or result in any change in the Company’s ul(cid:415)mate economic interest or control over the Philippine opera(cid:415)ons. The transac(cid:415)on is proposed to be accounted for as a common-control transac(cid:415)on in accordance with the applicable accoun(cid:415)ng framework. 3. Details of benefit, if any, to the The proposed ra(cid:415)onalisa(cid:415)on and consolida(cid:415)on is an promoter/promoter group/group internal reorganisa(cid:415)on of the Group’s exis(cid:415)ng Philippine companies from such proposed opera(cid:415)ons and does not envisage any specific benefit to the restructuring promoter or promoter group of the Company. 4. Brief details of change in There will be no change in the shareholding pa(cid:425)ern of the shareholding pa(cid:425)ern, if any, of all Company or in the ul(cid:415)mate ownership and control of the en(cid:415)(cid:415)es Philippine business. Nephrocare PH will con(cid:415)nue to remain a step-down subsidiary of the Company through Nephrocare Health Services Interna(cid:415)onal Pte. Ltd., Singapore. The proposed consolida(cid:415)on will result only in an internal reorganisa(cid:415)on of the ownership structure among the Philippine en(cid:415)(cid:415)es, without any change in the Company’s ul(cid:415)mate economic interest or control over the Philippine opera(cid:415)ons.